Lucid Diagnostics Financials
LUCD Stock | USD 1.56 0.06 4.00% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.64 | 0.68 |
|
|
The financial analysis of Lucid Diagnostics is a critical element in measuring its lifeblood. Investors should not minimize Lucid Diagnostics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Lucid | Select Account or Indicator |
Please note, the presentation of Lucid Diagnostics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lucid Diagnostics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Lucid Diagnostics' management manipulating its earnings.
Lucid Diagnostics Stock Summary
Lucid Diagnostics competes with Rxsight, Axogen, Pulmonx Corp, Orthofix Medical, and Orthopediatrics Corp. Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US54948X1090 |
CUSIP | 54948X109 |
Location | New York; U.S.A |
Business Address | 360 Madison Avenue, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.luciddx.com |
Phone | 917 813 1828 |
Currency | USD - US Dollar |
Lucid Diagnostics Key Financial Ratios
Return On Equity | -10.08 | ||||
Operating Margin | (9.98) % | ||||
Price To Sales | 29.95 X | ||||
Revenue | 2.43 M | ||||
Gross Profit | (2.22 M) |
Lucid Diagnostics Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Net Tangible Assets | (5.3M) | (13.5M) | (24.1M) | 19.6M | 22.5M | 23.7M | |
Retained Earnings | (13.8M) | (41.9M) | (98.1M) | (150.7M) | (135.7M) | (128.9M) | |
Accounts Payable | 2.1M | 1.5M | 1.1M | 1.1M | 1.3M | 1.3M | |
Total Current Assets | 1.4M | 57.3M | 24.4M | 22.1M | 25.4M | 19.4M | |
Common Stock | 14.1K | 35K | 41K | 42K | 48.3K | 28.6K | |
Total Assets | 2.2M | 59.0M | 32.5M | 27.3M | 31.4M | 26.8M | |
Other Current Liab | 13.7M | 2.8M | 6.4M | 13.2M | 15.2M | 9.1M | |
Net Debt | (111.3K) | (53.7M) | (20.5M) | (3.6M) | (3.3M) | (3.4M) | |
Cash | 111.3K | 53.7M | 22.5M | 18.9M | 21.7M | 21.0M | |
Other Assets | 755K | 725K | 1.1M | 1.0 | 0.9 | 0.86 | |
Inventory | 833.8K | 493K | 111K | 278K | 250.2K | 274.5K | |
Other Current Assets | 495K | 3.0M | 1.8M | 2.9M | 3.3M | 1.8M | |
Total Liab | 15.7M | 4.3M | 9.5M | 29.6M | 34.0M | 35.7M | |
Net Invested Capital | (13.5M) | 54.7M | 23.0M | (7.0M) | (8.0M) | (7.6M) | |
Capital Stock | 14.1K | 35K | 41K | 18.7M | 21.5M | 22.5M | |
Net Working Capital | (14.3M) | 53.0M | 15.9M | (7.3M) | (8.4M) | (8.0M) |
Lucid Diagnostics Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Ebit | (8.3M) | (27.4M) | (56.2M) | (52.3M) | (47.0M) | (44.7M) | |
Operating Income | (8.3M) | (27.4M) | (56.2M) | (48.5M) | (43.6M) | (45.8M) | |
Research Development | 5.4M | 9.3M | 11.5M | 7.3M | 8.3M | 8.1M | |
Ebitda | (8.3M) | (27.4M) | (54.2M) | (49.8M) | (44.8M) | (47.0M) | |
Income Before Tax | (8.3M) | (28.1M) | (56.2M) | (52.7M) | (47.4M) | (49.8M) | |
Net Income | (8.3M) | (28.7M) | (56.2M) | (52.7M) | (47.4M) | (49.8M) | |
Income Tax Expense | (8.3M) | 659K | 1.7M | 2.3M | 2.7M | 2.8M |
Lucid Diagnostics Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change In Cash | (45.1K) | 53.5M | (31.2M) | (3.6M) | (3.2M) | (3.1M) | |
Net Income | (8.3M) | (28.1M) | (56.2M) | (52.7M) | (47.4M) | (45.0M) | |
End Period Cash Flow | 111.3K | 53.7M | 22.5M | 18.9M | 21.7M | 17.5M | |
Change To Netincome | 173.9K | 65.5K | 9.6M | 13.9M | 15.9M | 16.7M | |
Investments | (10.3K) | (862K) | (4.1M) | (249K) | (224.1K) | (235.3K) | |
Free Cash Flow | (5.6M) | (18.5M) | (30.6M) | (33.0M) | (29.7M) | (28.2M) | |
Other Non Cash Items | (1.1M) | 10.5M | 653K | 4.9M | 5.6M | 3.2M |
Lucid Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lucid Diagnostics's current stock value. Our valuation model uses many indicators to compare Lucid Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lucid Diagnostics competition to find correlations between indicators driving Lucid Diagnostics's intrinsic value. More Info.Lucid Diagnostics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Lucid Diagnostics' Return On Equity is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lucid Diagnostics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Lucid Diagnostics Systematic Risk
Lucid Diagnostics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lucid Diagnostics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Lucid Diagnostics correlated with the market. If Beta is less than 0 Lucid Diagnostics generally moves in the opposite direction as compared to the market. If Lucid Diagnostics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lucid Diagnostics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lucid Diagnostics is generally in the same direction as the market. If Beta > 1 Lucid Diagnostics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Lucid Diagnostics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lucid Diagnostics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lucid Diagnostics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Lucid Diagnostics March 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lucid Diagnostics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lucid Diagnostics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lucid Diagnostics based on widely used predictive technical indicators. In general, we focus on analyzing Lucid Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lucid Diagnostics's daily price indicators and compare them against related drivers.
Downside Deviation | 5.04 | |||
Information Ratio | 0.2424 | |||
Maximum Drawdown | 35.88 | |||
Value At Risk | (5.21) | |||
Potential Upside | 8.9 |
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |